Jasemi Seyed Vahid, Zia Soha, Mirbahari Seyed Ghasem, Sadeghi Masoud
Department of Internal Medicine, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Kardiochir Torakochirurgia Pol. 2023 Dec;20(4):240-250. doi: 10.5114/kitp.2023.134177. Epub 2024 Jan 11.
The exact mechanism responsible for inflammation in malignancy is not completely understood, but it is possible that interleukin-6 (IL-6) plays a major role in triggering and maintaining an inflammatory response.
To conduct a systematic review and meta-analysis of the levels of IL-6 in the serum/plasma of lung cancer (LC) patients.
The researchers searched four databases up to September 11, 2022, to find studies that reported on IL-6 levels in LC patients compared to healthy controls (HCs). They calculated effect sizes using standardized mean difference (SMD) with a 95% confidence interval (CI). To evaluate the quality of each study, they used the Newcastle-Ottawa Scale (NOS). They performed subgroup analysis, sensitivity analysis, meta-regression analysis, heterogeneity analyses, trial sequential analysis, and publication bias with the trim-and-fill method.
The meta-analysis included 28 studies, and the results showed that the pooled SMD was 1.71 (95% CI: 1.22, 2.19; < 0.00001; = 98%), indicating that LC patients had significantly higher levels of IL-6 in their serum/plasma than HCs.
The study found that the publication year and quality score of the studies were positively associated with the level of IL-6, while the sample size was inversely related. The research suggests that measuring IL-6 levels in the blood could be useful for detecting and monitoring LC as it appears to be a reliable biomarker.
恶性肿瘤中炎症的确切机制尚未完全明确，但白细胞介素-6（IL-6）可能在引发和维持炎症反应中起主要作用。
对肺癌（LC）患者血清/血浆中IL-6水平进行系统评价和荟萃分析。
研究人员检索了截至2022年9月11日的四个数据库，以查找报告LC患者与健康对照（HCs）相比IL-6水平的研究。他们使用标准化均数差（SMD）及95%置信区间（CI）计算效应量。为评估每项研究的质量，他们使用了纽卡斯尔-渥太华量表（NOS）。他们进行了亚组分析、敏感性分析、Meta回归分析、异质性分析、试验序贯分析以及采用修剪填充法的发表偏倚分析。
荟萃分析纳入了28项研究，结果显示合并SMD为1.71（95%CI：1.22，2.19；P<0.00001；I² = 98%），表明LC患者血清/血浆中的IL-6水平显著高于HCs。
该研究发现，研究的发表年份和质量评分与IL-6水平呈正相关，而样本量与之呈负相关。该研究表明，检测血液中的IL-6水平可能有助于肺癌的检测和监测，因为它似乎是一种可靠的生物标志物。
